{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:16Z","timestamp":1772165656888,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["502-01-02225363-03679"],"award-info":[{"award-number":["502-01-02225363-03679"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["502-01-01124182-07474"],"award-info":[{"award-number":["502-01-01124182-07474"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In non-uremic subjects,\n                      <jats:italic>IFNL4<\/jats:italic>\n                      rs368234815 predicts HCV clearance. We investigated whether rs368234815 is associated with spontaneous HCV clearance in haemodialysis patients and whether it is a stronger predictor of HCV resolution than the\n                      <jats:italic>IFNL<\/jats:italic>\n                      polymorphisms already associated with HCV clearance in dialysis subjects. We also evaluated an association of rs368234815 with patients` survival and alterations in transcription factor binding sites (TFBS) caused by\n                      <jats:italic>IFNL<\/jats:italic>\n                      polymorphisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Among 161 haemodialysis patients with positive anti-HCV antibodies, 68 (42.2%) spontaneously resolved HCV infection, whereas 93 remained HCV RNA positive. Patients were tested for near\n                      <jats:italic>IFNL3<\/jats:italic>\n                      rs12980275,\n                      <jats:italic>IFNL3<\/jats:italic>\n                      rs4803217,\n                      <jats:italic>IFNL4<\/jats:italic>\n                      rs12979860,\n                      <jats:italic>IFNL4<\/jats:italic>\n                      rs368234815, and near\n                      <jats:italic>IFNL4<\/jats:italic>\n                      rs8099917.\n                      <jats:italic>IFNL4<\/jats:italic>\n                      rs368234815 polymorphism (TT\/TT, \u0394G\/TT, \u0394G\/\u0394G) was genotyped by restriction fragment length polymorphism analysis; other\n                      <jats:italic>IFNL<\/jats:italic>\n                      polymorphisms - by high resolution melting curve analysis. We used the Kaplan-Meier method with the log-rank test for survival analysis. In silico analysis included the use of ENCODE TFBS ChIP-seq data, HOCOMOCO, JASPAR CORE, and CIS-BP databases, and FIMO software.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The probability (OR, 95%CI, P) of spontaneous HCV clearance for rs368234815 TT\/TT patients was higher than for the \u0394G allele carriers (2.63, 1.38\u20135.04, 0.003). This probability for other major homozygotes varied between 2.80, 1.45\u20135.43, 0.002 for rs12980275 and 2.44, 1.27\u20134.69, 0.007 for rs12979860. In the additive model, rs368234815 TT\/TT was the strongest predictor of HCV clearance (6.38, 1.69\u201324.2, 0.003). Survival analysis suggested an association of the \u0394G allele with mortality due to neoplasms (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005). The rs368234815 \u2206G allele caused TFBS removal for PLAGL1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In haemodialysis patients, the association of rs368234815 with the spontaneous HCV clearance is better than that documented for other\n                      <jats:italic>IFNL3\/IFNL4<\/jats:italic>\n                      polymorphisms only in the additive mode of inheritance. However, identifying the homozygosity in the variant \u2206G allele of rs368234815 means a more potent prediction of persistent HCV infection in haemodialysis subjects that we observe in the case of the variant homozygosity of other tested\n                      <jats:italic>IFNL3<\/jats:italic>\n                      \/\n                      <jats:italic>IFNL4<\/jats:italic>\n                      polymorphisms. Removal of PLAGL1 TFBS in subjects harbouring the rs368234815 \u2206G allele may contribute to cancer susceptibility. The association of rs368234815 with cancer-related mortality needs further studies in HCV-exposed subjects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05777-6","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T02:03:21Z","timestamp":1611281001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-4696","authenticated-orcid":false,"given":"Alicja E.","family":"Grzegorzewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Mostowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika K.","family":"\u015awiderska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Marcinkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ireneusz","family":"Stolarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Figlerowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142 P.","family":"Jagodzi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"5777_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69\u201377.","journal-title":"Nat Immunol"},{"key":"5777_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63\u20138.","journal-title":"Nat Immunol"},{"key":"5777_CR3","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/srep16037","volume":"5","author":"YF Lu","year":"2015","unstructured":"Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037.","journal-title":"Sci Rep"},{"key":"5777_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20139.","journal-title":"Nat Genet"},{"key":"5777_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","volume":"139","author":"T Fukuhara","year":"2010","unstructured":"Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577\u201385.","journal-title":"Gastroenterology"},{"key":"5777_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798\u2013801.","journal-title":"Nature"},{"key":"5777_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338\u201345.","journal-title":"Gastroenterology"},{"key":"5777_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1128\/JCM.02139-10","volume":"49","author":"K Ito","year":"2011","unstructured":"Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon\/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853\u201360.","journal-title":"J Clin Microbiol"},{"key":"5777_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164\u201371.","journal-title":"Nat Genet"},{"key":"5777_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/jgh.12902","volume":"30","author":"M Murakawa","year":"2015","unstructured":"Murakawa M, Asahina Y, Nakagawa M, et al. Impaired induction of interleukin 28B and expression of interferon \u03bb 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2015;30:1075\u201384.","journal-title":"J Gastroenterol Hepatol"},{"key":"5777_CR11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ajpath.2015.11.027","volume":"186","author":"P Ferraris","year":"2016","unstructured":"Ferraris P, Chandra PK, Panigrahi R, et al. Cellular mechanism for impaired hepatitis C virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-\u03bb expression. Am J Pathol. 2016;186:938\u201351.","journal-title":"Am J Pathol"},{"key":"5777_CR12","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.1073\/pnas.1602319113","volume":"113","author":"AA Price","year":"2016","unstructured":"Price AA, Tedesco D, Prasad MR, et al. Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. Proc Natl Acad Sci U S A. 2016;113:10678\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5777_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/1735-1995.189678","volume":"21","author":"M Keshvari","year":"2016","unstructured":"Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci. 2016;21:72.","journal-title":"J Res Med Sci"},{"key":"5777_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/infdis\/jit433","volume":"209","author":"PV Aka","year":"2014","unstructured":"Aka PV, Kuniholm MH, Pfeiffer RM, et al. Association of the IFNL4-\u0394G allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014;209:350\u20134.","journal-title":"J Infect Dis"},{"key":"5777_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.20130012","volume":"210","author":"S Bibert","year":"2013","unstructured":"Bibert S, Roger T, Calandra T, et al. Swiss hepatitis C cohort study. IL28B expression depends on a novel TT\/\u2212G polymorphism which improves HCV clearance prediction. J Exp Med. 2013;210:1109\u201316.","journal-title":"J Exp Med"},{"key":"5777_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/QAD.0000000000000052","volume":"28","author":"S Franco","year":"2014","unstructured":"Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha\/ribavirin therapy failure in hepatitis C virus\/HIV-1 coinfected patients. AIDS. 2014;28:133\u20136.","journal-title":"AIDS"},{"key":"5777_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fcimb.2019.00340","volume":"9","author":"B Rugwizangoga","year":"2019","unstructured":"Rugwizangoga B, Andersson ME, Kabayiza JC, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.","journal-title":"Front Cell Infect Microbiol"},{"key":"5777_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jhep.2015.06.035","volume":"63","author":"TR O'Brien","year":"2015","unstructured":"O'Brien TR, Pfeiffer RM, Paquin A, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015;63:1103\u201310.","journal-title":"J Hepatol"},{"key":"5777_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100\u20134.","journal-title":"Nat Genet"},{"key":"5777_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.humimm.2016.05.007","volume":"77","author":"X Xie","year":"2016","unstructured":"Xie X, Zhang L, Chen YZ. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon\/ribavirin therapy: a meta-analysis. Hum Immunol. 2016;77:609\u201315.","journal-title":"Hum Immunol"},{"issue":"11","key":"5777_CR21","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/infdis\/jit827","volume":"209","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-\u0394G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700\u20134.","journal-title":"J Infect Dis"},{"issue":"7","key":"5777_CR22","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/ijms21072583","volume":"21","author":"PS Sung","year":"2020","unstructured":"Sung PS, Shin EC. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. Int J Mol Sci. 2020;21(7):2583.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5777_CR23","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.21608\/ejhm.2019.46756","volume":"77","author":"HE Zedan","year":"2019","unstructured":"Zedan HE, Talaat RM, Ammar AAA, Sakr MA. Interferon-lambda 4 gene polymorphisms predict treatment response in Egyptian HCV genotype 4 patients exposed to radiation. Egypt J Hosp Med. 2019;77(1):4748\u201353.","journal-title":"Egypt J Hosp Med"},{"key":"5777_CR24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.20452\/pamw.3205","volume":"125","author":"AE Grzegorzewska","year":"2015","unstructured":"Grzegorzewska AE, Jod\u0142owska E, Mostowska A, Jagodzi\u0144ski P. Effect of interferon \u03bb3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients. Pol Arch Med Wewn. 2015;125:894\u2013902.","journal-title":"Pol Arch Med Wewn"},{"key":"5777_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3109\/0886022X.2015.1061872","volume":"37","author":"P Dzekova-Vidimliski","year":"2015","unstructured":"Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Mena S, Rostaing L, Dimovski A, Sikole A. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Ren Fail. 2015;37:1180\u20134.","journal-title":"Ren Fail"},{"issue":"1","key":"5777_CR26","first-page":"A17","volume":"23","author":"AE Grzegorzewska","year":"2019","unstructured":"Grzegorzewska AE, Winnicka H, Warcho\u0142 W, Marcinkowski W, Mostowska A, Jagodzi\u0144ski PP. Effects of interferon-\u03bb3 gene polymorphic variants in response to HBV vaccination and outcome of HBV and HCV infections in hemodialysis patients. In: hemodialysis abstracts from the 39th annual Dialysis conference (Dallas). Hemodial Int. 2019;23(1):A17\u20138.","journal-title":"Hemodial Int"},{"key":"5777_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","volume":"60","author":"ML Yu","year":"2014","unstructured":"Yu ML. Dai CY, Huang CF, et al; FORMOSA-LIKE group. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol. 2014;60:253\u20139.","journal-title":"J Hepatol"},{"key":"5777_CR28","doi-asserted-by":"publisher","first-page":"F477","DOI":"10.1152\/ajprenal.00472.2015","volume":"310","author":"JL Rukov","year":"2016","unstructured":"Rukov JL, Gravesen E, Mace ML, et al. Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA-sequencing. Am J Physiol Renal Physiol. 2016;310:F477\u201391.","journal-title":"Am J Physiol Renal Physiol"},{"key":"5777_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/labmed\/lmw060","volume":"48","author":"M Pouryasin","year":"2017","unstructured":"Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C. Lab Med. 2017;48:51\u20136.","journal-title":"Lab Med"},{"key":"5777_CR30","doi-asserted-by":"publisher","first-page":"D56","DOI":"10.1093\/nar\/gks1172","volume":"41","author":"KR Rosenbloom","year":"2013","unstructured":"Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41:D56\u201363.","journal-title":"Nucleic Acids Res"},{"key":"5777_CR31","doi-asserted-by":"publisher","first-page":"D116","DOI":"10.1093\/nar\/gkv1249","volume":"44","author":"IV Kulakovskiy","year":"2016","unstructured":"Kulakovskiy IV, Vorontsov IE, Yevshin IS, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res. 2016;44:D116\u201325.","journal-title":"Nucleic Acids Res"},{"key":"5777_CR32","doi-asserted-by":"publisher","first-page":"D110","DOI":"10.1093\/nar\/gkv1176","volume":"44","author":"A Mathelier","year":"2016","unstructured":"Mathelier A, Fornes O, Arenillas DJ, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016;44:D110\u20135.","journal-title":"Nucleic Acids Res"},{"key":"5777_CR33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2014.08.009","volume":"158","author":"MT Weirauch","year":"2014","unstructured":"Weirauch MT, Yang A, Albu M, et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell. 2014;158:1431\u201343.","journal-title":"Cell"},{"key":"5777_CR34","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/bioinformatics\/btr064","volume":"27","author":"CE Grant","year":"2011","unstructured":"Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011;27:1017\u20138.","journal-title":"Bioinformatics"},{"key":"5777_CR35","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1093\/nar\/gki063","volume":"33","author":"DA Benson","year":"2005","unstructured":"Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res. 2005;33:D34\u20138.","journal-title":"Nucleic Acids Res"},{"key":"5777_CR36","doi-asserted-by":"publisher","first-page":"D204","DOI":"10.1093\/nar\/gku989","volume":"43","author":"UniProt Consortium","year":"2015","unstructured":"UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"5777_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263\u20135.","journal-title":"Bioinformatics"},{"key":"5777_CR38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple hypothesis testing. J R Stat Soc B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc B"},{"key":"5777_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.jrn.2011.10.020","volume":"22","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22:149\u201356.","journal-title":"J Ren Nutr"},{"key":"5777_CR40","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3748\/wjg.v23.i21.3815","volume":"23","author":"B \u015awi\u0105tek-Ko\u015bcielna","year":"2017","unstructured":"\u015awi\u0105tek-Ko\u015bcielna B, Ka\u0142u\u017cna E, Strauss E, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol. 2017;23:3815\u201324.","journal-title":"World J Gastroenterol"},{"key":"5777_CR41","doi-asserted-by":"publisher","first-page":"e31016","DOI":"10.1371\/journal.pone.0031016","volume":"7","author":"M de Castellarnau","year":"2012","unstructured":"de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Mart\u00ednez MA. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-\u03b1 and ribavirin therapy in HCV\/HIV-1 coinfected patients. PLoS One. 2012;7:e31016.","journal-title":"PLoS One"},{"issue":"5","key":"5777_CR42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41435-020-00115-3","volume":"21","author":"C Vergara","year":"2020","unstructured":"Vergara C, Duggal P, Thio CL, et al. Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes Immun. 2020;21(5):348\u201359.","journal-title":"Genes Immun"},{"issue":"4","key":"5777_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cells8040305","volume":"8","author":"D Lapa","year":"2019","unstructured":"Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay? Cells. 2019;8(4):305.","journal-title":"Cells"},{"issue":"11","key":"5777_CR44","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.4049\/jimmunol.1700807","volume":"199","author":"AA Obajemu","year":"2017","unstructured":"Obajemu AA, Rao N, Dilley KA, et al. IFN-\u03bb4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199(11):3808\u201320.","journal-title":"J Immunol"},{"issue":"11","key":"5777_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/jir.2013.0136","volume":"34","author":"TR O'Brien","year":"2014","unstructured":"O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-\u03bb4: the paradoxical new member of the interferon lambda family. J Interf Cytokine Res. 2014;34(11):829\u201338.","journal-title":"J Interf Cytokine Res"},{"key":"5777_CR46","doi-asserted-by":"publisher","first-page":"e42542","DOI":"10.7554\/eLife.42542","volume":"8","author":"N Chaturvedi","year":"2019","unstructured":"Chaturvedi N, Svarovskaia ES, Mo H, et al. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. Elife. 2019;8:e42542.","journal-title":"Elife"},{"issue":"4","key":"5777_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3350\/cmh.2014.20.4.368","volume":"20","author":"YK Cho","year":"2014","unstructured":"Cho YK, Kim YN, Song BC. Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol. 2014;20(4):368\u201375 Erratum in: Clin Mol Hepatol. 2015;21(1):104.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"5777_CR48","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/hep.25575","volume":"55","author":"L Liu","year":"2012","unstructured":"Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55(6):1684\u201391.","journal-title":"Hepatology"},{"key":"5777_CR49","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002;12:996\u20131006.","journal-title":"Genome Res"},{"issue":"21","key":"5777_CR50","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1158\/1078-0432.CCR-18-1060","volume":"24","author":"W Tang","year":"2018","unstructured":"Tang W, Wallace TA, Yi M, et al. IFNL4-\u0394G allele is associated with an interferon signature in tumors and survival of African-American men with prostate Cancer. Clin Cancer Res. 2018;24(21):5471\u201381.","journal-title":"Clin Cancer Res"},{"issue":"1 Supplement","key":"5777_CR51","first-page":"178","volume":"200","author":"OO Onabajo","year":"2018","unstructured":"Onabajo OO, Wang F, Banday R, Prokunina-Olsson L. Tumor transcriptome analysis and immune infiltrate profiling suggests a role for the IFNL3\/IFNL4 genomic locus in liver cancer. J Immunol. 2018;200(1 Supplement):178.","journal-title":"J Immunol"},{"key":"5777_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1089\/jir.2018.0046","volume":"39","author":"A Lasfar","year":"2019","unstructured":"Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon lambda: toward a dual role in cancer. J Interf Cytokine Res. 2019;39:22\u20139.","journal-title":"J Interf Cytokine Res"},{"key":"5777_CR53","unstructured":"PLAG1 like zinc finger 1 [ Homo sapiens (human) ]. Available at: https:\/\/www.ncbi.nlm.nih.gov\/gene\/5325. Accessed 24 Nov 2019."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05777-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:46:59Z","timestamp":1724345219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5777"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05777-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18966\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18966\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study design was approved by the Institutional Review Board of Poznan University of Medical Sciences, Poland. Written informed consent was obtained from all HD patients included in the study or their parents, as appropriate. All methods were performed under the Helsinki Declaration\u2019s ethical standards (1964, amended most recently in 2008), which was created by the World Medical Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}